June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
The Role of Endoglin in Retinal Neovascularization
Author Affiliations & Notes
  • Sandra Suarez
    Cell and Developmental Biology, Vanderbilt University, Nashville, TN
  • Joshua Barnett
    Pharmacology, Vanderbilt University, Nashville, TN
  • John Penn
    Ophthalmology and Visual Sciences, Vanderbilt Univ Medical Center, Nashville, TN
    Cell and Developmental Biology, Vanderbilt University, Nashville, TN
  • Footnotes
    Commercial Relationships Sandra Suarez, None; Joshua Barnett, None; John Penn, PanOptica (C), PanOptica (F), Alcon Laboratories (C), Alcon Laboratories (F), Centocor/Janssen (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5599. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sandra Suarez, Joshua Barnett, John Penn; The Role of Endoglin in Retinal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5599.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Anti-VEGF therapies are the current standard of care for treating diseases characterized by retinal or choroidal neovascularization (NV), such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). However, undesirable side effects and limited efficacy in certain subsets of patients have given rise to the exploration of non-VEGF-mediated therapies. Soluble endoglin (CD105) has been shown to be upregulated in the vasculature of certain tumors. The present study investigates the roles of hypoxia and VEGF on endoglin (CD105) expression in human retinal microvascular endothelial cells (HRMEC), and assesses the efficacy afforded by an endoglin antagonist in a rat model of oxygen-induced retinopathy (OIR).

Methods: HRMEC were exposed to hypoxia (4.6%CO2, 0.3%O2) or VEGF (25ng/mL) in culture medium containing 2% FBS, and endoglin expression was assessed by ELISA. Rats were exposed to OIR conditions, and endoglin expression was characterized by western blot analysis and immunohistochemistry (IHC). The effect of a dose range of blocking CD105 antibody on NV in OIR rats was determined by measurement of neovascular area (µm2).

Results: Hypoxia led to a significant increase in endoglin expression in HRMEC (p<0.001). Culture medium collected from HRMEC treated with VEGF also showed an increase in endoglin expression (p<0.01), but VEGF failed to elicit the same response in HRMEC lysates (p=0.35). Compared to controls, the retinas of OIR rats demonstrated increased early endoglin upregulation as determined by both western blot analysis and IHC. Increasing concentrations of anti-endoglin led to dose-dependent reductions in neovascular area in OIR-exposed rats: 18% (0.01 mg/mL), 31% (0.1 mg/mL; p<0.05), and 47% (1.0 mg/mL; p<0.05).

Conclusions: Preliminary investigation has confirmed a role for endoglin in the angiogenic endothelial cell response, and blocking this protein inhibits retinal NV in a clinically-relevant animal model. Thus, these findings suggest that endoglin may provide an efficacious and VEGF-independent strategy for disease conditions characterized by retinal or choroidal NV.

Keywords: 609 neovascularization • 548 hypoxia • 499 diabetic retinopathy  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.